Literature DB >> 2865161

Recovery of alpha 2-adrenoceptor binding and function after irreversible inactivation by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ).

C H Adler, E Meller, M Goldstein.   

Abstract

Treatment of rats with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) resulted in a pronounced loss of alpha 2-adrenoceptor binding ( [3H]RX-781094) and a marked reduction in the ability of the alpha 2-agonist UK-14,304 to inhibit K+-stimulated release of both [3H]NA and [3H]5-HT in cerebral cortex. Repopulation of alpha 2-adrenoceptors was monoexponential with a t1/2 of 4.1 days; functional recovery was also monoexponential, with t1/2 values of 2.4 and 4.6 days for restoration of alpha 2-mediated inhibition of [3H]NA and [3H]5-HT release, respectively. Other studies suggest the difference in functional recovery rate may reflect the presence of a large receptor reserve for autoreceptors relative to heteroreceptors.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2865161     DOI： 10.1016/0014-2999(85)90200-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN： 0014-2999            Impact factor:   4.432


  11 in total

1.  Differential protection and recovery of 5-HT1A receptors from N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) inactivation in regions of rat brain.

Authors:  K Y Vinod; M N Subhash; B N Srinivas
Journal:  Neurochem Res       Date:  2001-02       Impact factor: 3.996

2.  Further characterization of 5-HT1A receptors in the goldfish retina: role of cyclic AMP in the regulation of the in vitro outgrowth of retinal explants.

Authors:  C Schmeer; F Obregón; M Urbina; L Lima
Journal:  Neurochem Res       Date:  2001-03       Impact factor: 3.996

3.  Behavioural and physiological effects induced by an infusion of antisense to alpha(2D)-adrenoceptors in the rat.

Authors:  E S Robinson; D J Nutt; H C Jackson; A L Hudson
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

4.  Characterization of functional μ opioid receptor turnover in rat locus coeruleus: an electrophysiological and immunocytochemical study.

Authors:  María Carmen Medrano; María Teresa Santamarta; Patricia Pablos; Zigor Aira; Itsaso Buesa; Jon Jatsu Azkue; Aitziber Mendiguren; Joseba Pineda
Journal:  Br J Pharmacol       Date:  2017-07-07       Impact factor: 8.739

5.  Reciprocal interactions between alpha 2-adrenoceptor agonist and neuropeptide Y binding sites in the nucleus tractus solitarius of the rat. A biochemic and autoradiographic analysis.

Authors:  A Härfstrand; K Fuxe; L Agnati; B Fredholm
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

6.  Central alpha 2-autoreceptors: agonist dissociation constants and recovery after irreversible inactivation.

Authors:  E Agneter; H Drobny; E A Singer
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

7.  Effects of alpha 2-adrenoceptor agonists on locus coeruleus firing rate and brain noradrenaline turnover in N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ)-treated rats.

Authors:  G Engberg; E Eriksson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-05       Impact factor: 3.000

8.  Antisense technology reveals the alpha2A adrenoceptor to be the subtype mediating the hypnotic response to the highly selective agonist, dexmedetomidine, in the locus coeruleus of the rat.

Authors:  T Mizobe; K Maghsoudi; K Sitwala; G Tianzhi; J Ou; M Maze
Journal:  J Clin Invest       Date:  1996-09-01       Impact factor: 14.808

9.  Covariation of alpha 2-adrenoceptor density and function following irreversible antagonism with EEDQ.

Authors:  M J Durcan; P F Morgan; M L Van Etten; M Linnoila
Journal:  Br J Pharmacol       Date:  1994-07       Impact factor: 8.739

10.  Release-inhibiting alpha 2-adrenoceptors at serotonergic axons in rat and rabbit brain cortex: evidence for pharmacological identity with alpha 2-autoreceptors.

Authors:  A U Trendelenburg; M Trendelenburg; K Starke; N Limberger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-01       Impact factor: 3.000
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.